Oddbjorn Straume

Bergen, 5021, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

HIDE: hierarchical cell-type deconvolution.

HIDE: hierarchical cell-type deconvolution.

Journal: Bioinformatics (Oxford, England)
Published: July 15, 2025

Fundus hypopigmentation and choroidal thinning associated with tebentafusp therapy: report of a case and literature review.

Fundus hypopigmentation and choroidal thinning associated with tebentafusp therapy: report of a case and literature review.

Journal: BMC ophthalmology
Published: April 21, 2025

Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival.

Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival.

Journal: Oncoimmunology
Published: December 20, 2024

β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma.

β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma.

Journal: Cancer medicine
Published: March 08, 2023

Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature.

Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature.

Journal: Acta oncologica (Stockholm, Sweden)
Published: September 08, 2022

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.

Journal: ESMO open
Published: February 12, 2022

Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.

Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.

Journal: International journal of cancer
Published: May 07, 2021

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer.

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer.

Journal: Scientific reports
Published: May 14, 2020

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?

Journal: PharmacoEconomics - open
Published: January 29, 2020

Are 90% of deaths from cancer caused by metastases?

Are 90% of deaths from cancer caused by metastases?

Journal: Cancer medicine
Published: June 06, 2019

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 30, 2019

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.

Journal: Scientific reports
Published: November 27, 2018
Showing 1-12 of 33

Last Updated: 09/26/2026